• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AMRI and Biota strike development and manufacturing deal

AMRI and Biota strike development and manufacturing deal

April 18, 2012
CenterWatch Staff

AMRI, a global contract research and manufacturing organization, was selected by Biota Holdings, an Australian anti-infective drug development company, to further develop and manufacture influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

The deal sprouts from Biota’s desire to establish U.S. manufacturing of laninamivir, optimize its manufacturing processes, and conduct clinical trials for safety and efficacy in adult and pediatric populations. AMRI will provide these services to support a New Drug Application for laninamivir to the FDA.

AMRI's role will initially involve the development and manufacture of the active pharmaceutical ingredient for use in clinical trials. In the future there is the potential for AMRI to be selected as the commercial manufacturer of the product.

"The agreement with Biota demonstrates AMRI's global reputation as a preferred partner for delivering best-in-class drug discovery, development and manufacturing services," said AMRI's Chairman, President and CEO, Thomas E. D'Ambra, Ph.D. "We look forward to working with Biota to accelerate the advanced development of laninamivir."

In March 2011, the Office of Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services awarded Biota a five-year $231 million contract for the advanced development of laninamivir. The drug is already approved for sale in Japan and was launched as Inavir by Daiichi Sankyo in October 2010. It is not currently approved for sale in other markets.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing